# Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

> **NCT02311621** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Seattle Children's Hospital** · enrollment: 65 (estimated)

## Conditions studied

- Neuroblastoma
- Ganglioneuroblastoma

## Interventions

- **BIOLOGICAL:** Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)
- **BIOLOGICAL:** Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)
- **BIOLOGICAL:** Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)

## Key facts

- **NCT ID:** NCT02311621
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-11-25
- **Primary completion:** 2023-11
- **Final completion:** 2038-11
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-05-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02311621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02311621, "Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02311621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*